tradmap

BIO Financials Bio-Rad Laboratories, Inc.

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Growth & profitability

  • Revenue has grown 0.3% per year over the past 5 years.
  • Net income has grown slower than revenue (-27.6% vs 0.3% per year).
  • Operating margin has contracted, at 1.8% in the latest year.
  • Free cash flow has declined 4.7% per year over the past 5 years.

Financial health

  • Total debt ($1.2B) exceeds cash ($530M); net debt is $673M.
  • Total debt has grown faster than revenue (150.2% vs 0.3% per year).
  • Operating income covered interest expense 1.0× in the latest year, down from 19× 5 years ago.
  • Total debt is 5.7× EBITDA.
Revenue & net income
-$4B $313M $4B $0 2011 2013 2015 2017 2019 2021 2023 2025
RevenueNet income
Margins (gross / operating / net)
-129% 10% 150% 0% 2011 2013 2015 2017 2019 2021 2023 2025
GrossOperatingNet
Free cash flow (CFO − capex)
-$7M $264M $536M $0 2011 2013 2015 2017 2019 2021 2023 2025
Free cash flow
Cash vs total debt
$0 $605M $1B 2011 2013 2015 2017 2019 2021 2023 2025
CashTotal debt
Cash flow: operating / investing / financing
-$1B -$117M $974M $0 2011 2013 2015 2017 2019 2021 2023 2025
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MFCFTotal debtCash
2025 $2.6B $760M 51.9% 1.8% $375M $1.2B $530M
2024 $2.6B -$1.8B 53.7% 10.5% $290M $1.2B $488M
2023 $2.7B -$637M 53.4% 12.6% $218M $1.2B $404M
2022 $2.8B -$3.6B 55.9% 17.2% $82M $1.2B $434M
2021 $2.9B $4.3B 56.1% 17.1% $536M $11M $471M
2020 $2.5B $3.8B 56.5% 16.6% $476M $12M $662M
2019 $2.3B $1.8B 54.4% 9.9% $359M $14M $661M
2018 $2.3B $366M 53.4% -4.5% $156M $439M $432M
2017 $2.2B $122M 55.0% 5.5% -$7M — $384M
2016 $2.1B $26M 55.0% 2.7% $75M — $456M
2015 — $109M — — $74M — $458M
2014 — $89M — — $152M — $413M
2013 — $78M — — $62M $436M $332M
2012 — $165M — — $124M $733M $463M
2011 — $179M — — $160M $732M $574M

Valuation over time

How the market has priced BIO against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

Price / earnings (P/E)
0.0 5.5 11.1 Mar '23 Aug '23 Jan '24 Jun '24 Nov '24 Apr '25 Sep '25 Feb '26
P/E
Price / sales (P/S)
0.0 2.3 4.6 Mar '23 Aug '23 Jan '24 Jun '24 Nov '24 Apr '25 Sep '25 Feb '26
P/S

Frequently asked questions

Is BIO growing its revenue and profit?

Over the past 5 years, Bio-Rad Laboratories, Inc.'s revenue has grown 0.3% per year, and net income declined 27.6% per year. These are computed facts, not advice.

How much debt does BIO have?

As of FY2025, Bio-Rad Laboratories, Inc. reported $1.2B of total debt against $530M of cash; operating income covered interest expense 1.0×.

What is BIO's profit margin?

In FY2025, gross margin was 51.9%, operating margin 1.8%, and net margin 29.4%.

What is BIO's P/E ratio?

As of Jun '26, Bio-Rad Laboratories, Inc. traded at a price-to-earnings ratio of about 10.6× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.